扶正解毒方联合吉西他滨和顺铂对晚期非小细胞肺癌患者T细胞亚群和血清肿瘤标志物的影响

目的:探讨扶正解毒方联合吉西他滨和顺铂对晚期非小细胞肺癌(NSCLC)患者T细胞亚群和血清肿瘤标志物的影响。方法:选取2017年3月2018年12月期间我院接受的晚期NSCLC患者80例,根据随机数字法将患者分为对照组(n=40,给予吉西他滨和顺铂治疗)和研究组(n=40,给予扶正解毒方联合吉西他滨和顺铂治疗)。比较两组患者疗效、T细胞亚群和血清肿瘤标志物,记录两组不良反应发生情况。结果:研究组治疗4个周期后的临床总有效率高于对照组(P<0.05)。两组治疗4个周期后CD3⁺、CD4⁺、CD4⁺/CD8⁺均较治疗前下降,但研究组高于对照组(P<0.05);两组治疗4个周期后CD8⁺较治疗前升高,但研究组低于对照组(P<0.05)。两组治疗4个周期后癌胚抗原(CEA)、糖类抗原125(CA125)及糖类抗原199(CA199)水平均较治疗前降低,且研究组低于对照组(P<0.05)。两组不良反应发生率比较差异无统计学意义(P>0.05)。结论:扶正解毒方联合吉西他滨和顺铂治疗晚期NSCLC患者,疗效较好,可有效阻止疾病进展,减轻免疫抑制,且用药安全性佳,具有一定的临床应用价值。

Effect of Fuzheng Jiedu Formula Combined with Gemcitabine and Cisplatin on T Cell Subsets and Serum Tumor Markers in Patients with Advanced Non-small Cell Lung Cancer

ABSTRACT Objective: To investigate the effect of Fuzheng Jiedu formula combined with gemcitabine and cisplatin on T cell subsets and serum tumor markers in patients with advanced non-small cell lung cancer (NSCLC). Methods: 80 patients with advanced NSCLC who were admitted to our hospital from March 2017 to December 2018 were selected, patients were divided into control group (n=40, treatmented with gemcitabine and cisplatin) and study group (n=40, treatmented with Fuzheng Jiedu Fang combined with gemcitabine and cisplatin) according to the random number method. The therapeutic effect, T cell subsets and serum tumor markers were compared between the two groups, and the adverse reactions of two groups were recorded. Results: The total clinical effective rate of the study group at 4 cycles after treatment was higher than that of the control group (P<0.05). CD3⁺, CD4⁺, CD4⁺/CD8⁺ in the two groups at 4 cycles after treatment decreased compared with those before treatment, but the study group was higher than the control group (P<0.05). CD8+ in the two groups at 4 cycles after treatment increased compared with that before treatment, but the study group was lower than the control group (P<0.05). The levels of carcinoembryonic antigen (CEA), carbohydrate antigen 125 (CA125) and carbohydrate antigen 199 (CA199) of the two groups at 4 cycles after treatment were lower than those before treatment, the study group was lower than the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: Fuzheng Jiedu formula combined with gemcitabine and cisplatin in the treatment of advanced NSCLCpatients, the effect is good, which can effectively prevent the progress of disease, reduce the immunosuppression, and has a good safety, and which has a certain clinical application value.